Mental Health Interventions in Refractory Chronic Spontaneous Urticaria: A Call to Expand Treatment Guidelines

Chronic spontaneous urticaria (CSU) is a complex inflammatory skin condition that severely impacts patients' quality of life. For some patients, conventional treatments, including second-generation antihistamines, omalizumab, and cyclosporine A, fail to achieve sustained control. Emerging evidence suggests that psychiatric comorbidities, such as generalized anxiety disorder (GAD), exacerbate CSU through neuro-immuno-cutaneous (the interaction between the nervous system, immune system, and skin) mechanisms. We present the case of a 35-year-old female with refractory CSU and GAD. Despite escalating doses of omalizumab and the addition of cyclosporine A, disease control remained unstable. The introduction of cognitive behavioral therapy (CBT) and escitalopram resulted in significant improvement, achieving complete resolution of symptoms within eight weeks. Following discontinuation of both escitalopram and omalizumab, urticaria relapsed after a stressful event and during pregnancy. The reintroduction of escitalopram and CBT reestablished full control of urticaria. The patient continues on escitalopram and CBT without needing additional pharmacological intervention for CSU. This case underscores the importance of incorporating mental health interventions in managing refractory CSU, as psychiatric comorbidities may exacerbate CSU by intensifying neuro-immune interactions, particularly during stressful periods. Integrating mental health care into treatment guidelines can offer significant benefits, improving symptom control, reducing the need for aggressive pharmacotherapy, and enhancing patients' quality of life.